Familial hypercholesterolemia is one of the most common inherited genetic conditions, affecting an estimated 1 in 200 to 250 people worldwide. It causes dangerously elevated LDL cholesterol from birth, significantly increasing the lifetime risk of coronary artery disease, heart attack, and stroke. People with FH face a 20-fold increased risk of premature coronary heart disease compared to the general population. If left untreated, women face a 30% risk of a cardiac event by age 60 and men face a 50% risk by age 50. It is also highly treatable. Yet most people who have it do not know.
A large-scale study published in Circulation: Genomic and Precision Medicine examined exome sequencing data from more than 84,000 participants across three Mayo Clinic sites to assess whether genetic screening could identify individuals with familial hypercholesterolemia (FH) who were being missed by standard clinical criteria. The findings are striking: nearly 90% of those identified were newly diagnosed, and fewer than one in three confirmed genetic cases met standard clinical guidelines for testing.
What the Study Found
The Tapestry study recruited participants across Mayo Clinic sites in Arizona, Florida, and Minnesota. Each participant underwent exome sequencing, which reads the protein-coding regions of the genome where most disease-causing variants are found. Researchers specifically looked for pathogenic variants in three genes known to cause FH: LDLR, APOB, and PCSK9.
Of the 84,413 participants, 419 carried likely pathogenic or pathogenic FH variants, a prevalence of approximately 0.5%. The majority had no prior diagnosis. Standard clinical criteria, which rely on cholesterol levels and family history, identified fewer than one in three of those confirmed cases.
The consequences of that missed detection were already visible. At the time of identification, 22% of FH carriers in the study already had a documented history of coronary artery disease. Only 10% were at their LDL cholesterol goal.
Why Standard Guidelines Fall Short
Current clinical criteria for FH testing are built around two primary signals: significantly elevated LDL cholesterol and a family history of premature cardiovascular disease. While these criteria identify some high-risk individuals, the study demonstrates they create a significant blind spot.
FH is an autosomal dominant condition, meaning a single copy of a pathogenic variant is sufficient to cause disease. It passes silently through families, often for generations, without triggering the cholesterol thresholds or family history patterns that current guidelines use as triggers for testing. Many carriers have LDL levels that are elevated but not dramatic enough to prompt genetic investigation. Many have no documented family history, not because the history does not exist, but because other family members were also never diagnosed.
The result is a large group of people carrying a treatable genetic risk factor who are identified only after cardiovascular disease has already developed, if they are identified at all.
The Case for Earlier Genomic Identification
The study's authors conclude that wider use of germline genetic sequencing is needed to enhance screening and detection of individuals with FH. The rationale is straightforward: FH is common, it is serious, and it is actionable. Statins and other lipid-lowering therapies are highly effective when started early. The window for prevention is widest before cardiovascular disease develops, not after.
Without treatment, the average age of first heart attack in someone with heterozygous FH is 35. In the rarer homozygous form, where pathogenic variants are inherited from both parents, that figure drops to just 14 years old. These are not edge-case statistics. They are the expected trajectory without early identification and intervention.
This is where genomic identification changes the clinical equation. Rather than waiting for a cholesterol threshold to be crossed or a family member to experience a cardiac event, genomic screening can identify at-risk individuals proactively, at a point when intervention has the greatest preventive impact.
From Identification to Action
Detection alone does not change outcomes. What determines whether a genomic finding translates into meaningful prevention is what happens next: whether the result is formally documented, communicated clearly, and connected to a treatment pathway.
This is a critical practical consideration for clinicians. The study found that only 10% of identified FH carriers were at LDL goal at the time of identification, and more than a quarter were not on any cholesterol-lowering medication at all. Genomic identification creates the opportunity to change that, but only if it is followed by structured clinical action. Genetic counselling, clear result communication, and defined referral pathways are what convert a positive genomic finding into a prevention strategy.
Implications for Clinical Practice
FH is not a rare or exotic condition. At a prevalence of approximately 1 in 200, it is one of the more common inherited conditions a GP or cardiologist will encounter in a general patient population, most of whom will never have been flagged by standard screening criteria.
The practical takeaway from this study is that cholesterol levels and family history alone are not sufficient to identify most people at genetic risk of premature cardiovascular disease. Genomic testing, interpreted within a structured clinical pathway, offers a more complete picture and, critically, identifies risk at a point when it can still be acted upon.
For patients with moderately elevated LDL who do not meet standard testing criteria, or those with a family history that is unclear or undocumented, genomic assessment may be the more appropriate next step than continued monitoring alone.
Looking Forward
The Tapestry study is one of the largest real-world assessments of FH detection through population genomic screening. Its findings reflect a broader shift in how inherited cardiovascular risk is being approached: moving from reactive identification after disease develops toward proactive risk stratification before it does.
As genomic testing becomes more accessible and better integrated into clinical workflows, the question for practice is not whether to incorporate genetic information into cardiovascular risk assessment, but how to do so in a way that is structured, interpretable, and connected to clear clinical action.
Reference: Samadder, N.J., Schroeder, M., Voss, M.M. et al. Exome Sequencing Enhances Screening for Familial Hypercholesterolemia Within a Multi-Site Healthcare System. Circ Genom Precis Med 18, e005174 (2025). https://doi.org/10.1161/CIRCGEN.125.005174
